Dense sheur tissue and tumors appear to be the same as scans, which can make later recognition
Gorodenkoff / Shutterstock
If you have dark breast tissue, you can benefit from an increased phase of CANCER Screening, according to a large test found this seized mammograms unknown to standard mammograms.
The UK HEALTH Services offer mammograms, a form of x-ray scan, between the ages of 50 and 71 to screen breast cancer. It is looking for white growth indicating cancer. But about half of the women in this age group there are dark breastsmeans they have a long proportion to fibrous and glandular tissue, which also appears white on scans. These boils can make it more difficult to see these individuals.
“The problem with the flattery chests we can see the cancers are late, then they are greater and this is the cause of a bad prognosis,” as Thomas Helbuch At the Medical University of Vienna in Austria, which is not included in the test.
To see if additional screening can solve it, Sarah Vinnicombe At the University of Dundee, UK, and his colleagues recruit more than 6000 females aged 50 to 70 from across the UK with passionate chests and whose mammograms return to their most recent screening. Researchers randomly divided participants in three groups who received additional screening in the form of an MRI, an ultrasound or an advanced form of X-ray scan that is called contract-clilict mammography.
Excessive screening collectively found 85 small tumors, with MRI and contrastst-dechented mammography found three times more boils than ultrasound. Twelve of these boils attached within the dairy ducts and therefore cannot spread ahead of the chest. But the remaining 73 tumors invades, if cancer cells grow by the line of ducts in the adjacent chest tissue and then there is a greater potential to spread.
“It is very important to find these cancers; they usually grow and if you see them three, four years ago, they are larger than size,” said Helbobich. “As some may be aggressive, I am sure the supplemental screening can save lives.”
But we don’t know if this is exactly what happens. For example, a 2021 TRIALS In the screening of ovarian cancer causes a decrease in the situation, but not translated into lives saved. It is also possible that some of the found tumors are non-cancer or cannot be spread. If this is the case, supplemental screening can lead to unnecessary concern or DRUGS.
Team plans to keep track of participants to help the gauge if additional screening can help save lives and justify the cost of rolling it, says Vinnicombe.
Topics:
